NICE rebuffs Adcetris for Hodgkin's lymphoma

In preliminary draft guidance, the U.K.'s NICE recommended against Adcetris brentuximab vedotin from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for CD30-positive Hodgkin's lymphoma.

The agency said evidence supporting Adcetris' clinical effectiveness and mortality benefit is "immature and limited," noting that most of the data in the company's submission were related to anti-tumor efficacy as evaluated by response rate, rather than progression-free survival (PFS) and overall survival (OS). Comments on the draft guidance are due Sept. 1. ...